目的观察化疗联合应用帕米膦酸钠治疗肿瘤骨转移的疗效。方法 60例肿瘤骨转移患者均分为两组,A组为化疗联合应用帕米膦酸钠,B组仅单纯化疗。记录治疗前、后体力状况评分(KPS)、疼痛评分(NRS)和血清碱性磷酸酶(AKP)浓度变化。结果治疗2个周期后,两组血清AKP水平明显低于治疗前,且A组AKP下降程度大于B组(P<0.05)。治疗后,两组NRS评分有明显降低,而KPS评分有明显升高(P<0.05),且A组改善效果较B组更好。A组疼痛缓解率为66.67%,明显高于B组的46.67%(P<0.05)。治疗期间无骨相关事件发生。结论化疗联合应用帕米膦酸钠治疗肿瘤骨转移性疼痛疗效优于单纯化疗;血清AKP可作为疗效评估指标。 Objective To observe the curative effect of chemotherapy combined with pamidronate in the treatment of tumor bone metastasis. Methods Sixty patients with tumor metastasis were divided into two groups: group A received chemotherapy combined with pamidronate, and group B received chemotherapy alone. Record before and after treatment physical status score (KPS), pain score (NRS) and serum alkaline phosphatase (AKP) concentration changes. Results After 2 cycles of treatment, serum AKP levels in both groups were significantly lower than those before treatment, and AKP levels in group A were significantly lower than those in group B (P <0.05). After treatment, NRS scores decreased significantly in both groups, while KPS scores increased significantly (P <0.05), and the improvement effect of A group was better than that of B group. The pain relief rate in group A was 66.67%, significantly higher than that in group B (46.67%, P <0.05). No bone-related events occurred during treatment. Conclusions Chemotherapy combined with pamidronate is superior to chemotherapy alone in treating bone metastatic pain. Serum AKP can be used as an index of curative effect.